Feline sporotrichosis is a public health concern because it is a zoonotic illness and has a prolonged treatment time. We report laboratory-confirmed cases of feline Sporothrix schenckii complex infection submitted to a laboratory in Thailand during 2023–2025 and evaluate their in vitro antifungal drug susceptibility profiles for amphotericin B, itraconazole, posaconazole, voriconazole, ketoconazole, fluconazole, and flucytosine.
schenckii complex isolates were identified. Overall, 368 isolates did not show reduced susceptibility.
We observed single-drug reduced susceptibility to amphotericin B (60 isolates), posaconazole (41 isolates), voriconazole (9 isolates), and terbinafine (4 isolates). We observed a reduced susceptibility to itraconazole in 687 isolates: 321 single-drug, 270 co-reduced, and 96 multidrug-reduced isolates.
An increasing number of feline sporotrichosis cases and escalating reduced susceptibility to itraconazole underscore the need for continued surveillance and susceptibility testing to support management in complex cases.